Antidepressant combination drug
AssigneeNishizaki Bioinformation Research Institute
InventorTomoyuki NISHIZAKI
Life of this patent
Estimating the term…
Abstract
The combined use of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine affords a superior anti-depressive action, an improving effect on the cognitive function associated with depression, an improving effect on the stress-induced suppression of Akt activation, and a suppressive action on the stress-induced GSK-3β activation. Therefore, the present invention can provide an antidepressant combination drug, an agent for improving cognitive function associated with depression, an agent for improving stress-induced suppression of Akt activation and an agent for suppressing stress-induced GSK-3β activation.
Claims9
-6. (canceled)
A method of improving stress-induced suppression of Akt activation, comprising treating cells or tissues with 1,2-dilinoleoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine.
A method of improving stress-induced suppression of Akt activation, comprising administering an effective amount of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine and an effective amount of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine in combination to a target in need thereof.
Dependencies are inferred from the claim text.